We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merck's Antibiotic Recarbrio Gets FDA Nod for New Indication
Read MoreHide Full Article
Merck & Co., Inc. (MRK - Free Report) announced that the FDA has approved the supplemental new drug application (sNDA) for its new antibacterial injection Recarbrio for a new indication. Recarbrio is now approved to treat adult patients with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by certain susceptible Gram-negative microorganisms.
Merck filed the sNDA seeking approval for Recarbrio to address the HABP/VABP indication in February.
The sNDA was based on the results of the pivotal phase III RESTORE-IMI 2 study. In the same, Recarbrio met both the primary and key secondary endpoints by demonstrating non-inferiority to PIP/TAZ in a 28-day all-cause mortality and clinical response at early follow-up, respectively.
Recarbrio is a fixed combination of relebactam and imipenem/cilastatin. It was approved for the treatment of adults with complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI) caused by certain susceptible gram-negative bacteria in July 2019.
Shares of Merck have declined 9.6% in the year so far compared with the industry’s decrease of 1.3%.
We note that Recarbrio received the FDA’s Qualified Infectious Disease Product (QIDP) designation for the treatment of cUTI and cIAI. QIDP is a designation granted to antibacterial or antifungal drugs for human use, intended to treat serious or life-threatening infections. This designation can boost the drug’s sales in the days ahead.
Merck’s antibacterial medicine Zerbaxa is also approved for HABP/VABP. Zerbaxa, a combination of ceftolozane and tazobactam, is also marketed for some complicated urinary tract infections.
Zacks Rank and Stocks to Consider
Merck currently has a Zacks Rank #3 (Hold). Better-ranked stocks in the large-cap pharma sector include Eli Lilly and Company (LLY - Free Report) , AbbVie Inc. (ABBV - Free Report) and AstraZeneca (AZN - Free Report) . While Eli Lilly and AbbVie currently sport a Zacks Rank #1 (Strong Buy), AstraZeneca presently holds a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Eli Lilly’s earnings estimates have been revised 0.6% upward for 2020 and 1% for 2021 over the past 60 days. The stock has gained 13.6% year to date.
AbbVie earnings estimates have been revised 14.2% upward for 2020 and 6.6% for 2021 over the past 60 days. The stock has inched up 5.9% year to date.
AstraZeneca’s earnings estimates have moved 0.5% north for 2020 and 0.8% for 2021 over the past 60 days. The stock has rallied 8% year to date.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Image: Shutterstock
Merck's Antibiotic Recarbrio Gets FDA Nod for New Indication
Merck & Co., Inc. (MRK - Free Report) announced that the FDA has approved the supplemental new drug application (sNDA) for its new antibacterial injection Recarbrio for a new indication. Recarbrio is now approved to treat adult patients with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by certain susceptible Gram-negative microorganisms.
Merck filed the sNDA seeking approval for Recarbrio to address the HABP/VABP indication in February.
The sNDA was based on the results of the pivotal phase III RESTORE-IMI 2 study. In the same, Recarbrio met both the primary and key secondary endpoints by demonstrating non-inferiority to PIP/TAZ in a 28-day all-cause mortality and clinical response at early follow-up, respectively.
Recarbrio is a fixed combination of relebactam and imipenem/cilastatin. It was approved for the treatment of adults with complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI) caused by certain susceptible gram-negative bacteria in July 2019.
Shares of Merck have declined 9.6% in the year so far compared with the industry’s decrease of 1.3%.
We note that Recarbrio received the FDA’s Qualified Infectious Disease Product (QIDP) designation for the treatment of cUTI and cIAI. QIDP is a designation granted to antibacterial or antifungal drugs for human use, intended to treat serious or life-threatening infections. This designation can boost the drug’s sales in the days ahead.
Merck’s antibacterial medicine Zerbaxa is also approved for HABP/VABP. Zerbaxa, a combination of ceftolozane and tazobactam, is also marketed for some complicated urinary tract infections.
Zacks Rank and Stocks to Consider
Merck currently has a Zacks Rank #3 (Hold). Better-ranked stocks in the large-cap pharma sector include Eli Lilly and Company (LLY - Free Report) , AbbVie Inc. (ABBV - Free Report) and AstraZeneca (AZN - Free Report) . While Eli Lilly and AbbVie currently sport a Zacks Rank #1 (Strong Buy), AstraZeneca presently holds a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Eli Lilly’s earnings estimates have been revised 0.6% upward for 2020 and 1% for 2021 over the past 60 days. The stock has gained 13.6% year to date.
AbbVie earnings estimates have been revised 14.2% upward for 2020 and 6.6% for 2021 over the past 60 days. The stock has inched up 5.9% year to date.
AstraZeneca’s earnings estimates have moved 0.5% north for 2020 and 0.8% for 2021 over the past 60 days. The stock has rallied 8% year to date.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>